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Abstract
Background: HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been
associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively
evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients
treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy.
Methods: In a series of 352 breast carcinoma tissues from patients that had been post-operatively treated with
epirubicin-CMF with or without paclitaxel, we assessed HER2 and TOP2A gene status (chromogenic in situ
hybridization), mRNA expression (quantitative reverse transcription PCR), as well as HER2 and TopoIIa protein
expression (immunohistochemistry).
Results: HER2 and TOP2A amplification did not share the same effects on their downstream molecules, with
consistent patterns observed in HER2 mRNA and protein expression according to HER2 amplification (all
parameters strongly inter-related, p values < 0.001), but inconsistent patterns in the case of TOP2A. TOP2A gene
amplification (7% of all cases) was not related to TOP2A mRNA and TopoIIa protein expression, while TOP2A mRNA
and TopoIIa protein were strongly related to each other (p < 0.001). Hence, TOP2A amplified tumors did not
correspond to tumors with high TOP2A mRNA or TopoIIa protein expression, while the latter were characterized by
high Ki67 scores (p = 0.003 and p < 0.001, respectively). Multivariate analysis adjusted for nodal involvement,
hormone receptor status, Ki67 score and HER2/TOP2A parameters revealed HER2/TOP2A co-amplification (21.2% of
HER2 amplified tumors) as an independent favorable prognostic factor for DFS (HR = 0.13, 95% CI: 0.02-0.96, p =
0.046); in contrast, increased HER2/TOP2A mRNA co-expression was identified as an independent adverse
prognostic factor for both DFS (HR = 2.41, 95% CI: 1.31-4.42, p = 0.005) and OS (HR = 2.83, 95% CI: 1.42-5.63, p =
0.003), while high TOP2A mRNA expression was an independent adverse prognostic factor for OS (HR = 2.06, 95%
CI: 1.23-3.46, p = 0.006). None of the parameters tested was associated with response to paclitaxel.
Conclusions: This study confirms the favorable prognostic value of HER2/TOP2A co-amplification and the adverse
prognostic value of high TOP2A mRNA expression extending it to the adjuvant treatment setting in early high-risk
breast cancer. The strong adverse prognostic impact of high HER2/TOP2A mRNA co-expression needs further
validation in studies designed to evaluate markers predictive for anthracyclines.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12611000506998.
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Introduction
Adjuvant chemotherapy is known to prolong disease-
free survival (DFS) and overall survival (OS) in patients
with early-stage breast cancer (EBCTCG [1]). Moreover,
anthracyclines and taxanes are currently considered to
be essential drugs in this setting [2]. However, the indis-
criminate administration of these drugs and especially of
anthracyclines results in late life-threatening toxicities,
such as congestive heart failure and acute leukemia or
myelodysplasia, in 0.3 to 3% of the patients [3,4]. The
above potential risks point out the importance of the
identification of biological markers, which would sepa-
rate patient subgroups with favorable prognosis and
thus spare them the potential risks of such toxic
treatment.
HER2 gene amplification and/or protein overexpres-
sion has been identified in approximately 20% of inva-
sive breast cancer patients [5] and was shown to be
associated with a worse prognosis [6]. HER2 gene ampli-
fication has been evaluated as a predictive factor for dif-
ferent cytotoxic drugs, including anthracyclines and
paclitaxel [7,8]. Interestingly, most relevant studies and
a meta-analysis [9] provided compelling evidence that
the benefit from adjuvant anthracyclines is restricted to
the HER2-positive subgroup of patients. Nevertheless,
these results have been challenged by other investiga-
tors, especially in patients with metastatic disease
[10,11]. Taken together, these findings raise the possibi-
lity that other than HER2 genes, located on chromo-
some 17, may be key regulators of anthracycline
responsiveness [7].
O n es u c hg e n ei st o p o i s o m e r a s eI Ia l p h a( T O P 2 A ) ,
which is located ~700 kb telomeric to HER2 and
encodes a cell-cycle regulator. TOP2A is a key player in
DNA replication and remodeling and, in the context of
cytotoxic chemotherapy, a molecular target for anthra-
cyclines and other chemotherapeutic agents [12,13].
TOP2A gene is co-amplified in 30%-40% of the tumors
with HER2 gene amplification, while deletions are also
frequently observed [14]. The puzzle on the possible
prognostic/predictive role of TOP2A is complicated by
studies suggesting that topoisomerase II alpha protein
expression (TopoIIa), rather than TOP2A gene amplifi-
cation, is predictive of anthracycline responsiveness in
the adjuvant setting [15].
HER2 and TOP2A gene amplification testing is mostly
performed by fluorescent in situ hybridization (FISH) or
chromogenic in situ hybridization (CISH) [16]. However,
neither of these two molecular techniques is
characterized by high resolution for gene mapping and
may easily miss gene-specific microdeletions identified
by other approaches, such as PCR-based methods.
Based upon this information we performed a compre-
hensive evaluation of HER2 and TOP2A parameters in
tumors from patients that had participated in the Helle-
nic Cooperative Oncology Group (HeCOG) phase III
trial HE10/97 [17]. The objective of this trial had been
the evaluation of the efficacy of epirubicin-based dose-
dense sequential regimens with and without paclitaxel
in patients with high-risk operable breast cancer. In the
present study, we sought to investigate HER2 and
TOP2A parameters at three different levels (gene status,
mRNA expression and protein expression) in association
with classic clinicopathological parameters, as well as to
evaluate their impact on patient outcome. Clearly, since
prognostic and predictive factors represent distinct
means for assessing clinical outcome [18], and since all
our patients had been treated with an anthracycline, it
was possible to investigate for prognostic factors and
not for factors predicting response to anthracyclines in
the present setting. However, since paclitaxel had been
added to the regimen in half of the cases, we also evalu-
ated HER2 and TOP2A parameters as markers predic-
tive for response to this agent.
Patients and methods
Patients and tissues
Formalin-fixed paraffin-embedded (FFPE) tumor tissue
samples were retrospectively collected from 367 patients
that had participated in a phase III trial (HE 10/97); in that
trial, 595 eligible high-risk breast cancer patients were ran-
domized to receive postoperative dose-dense sequential
chemotherapy with 3 cycles of epirubicin 110 mg/m
2, fol-
lowed by 3 cycles of paclitaxel (Taxol™, Bristol-Myers
Squibb, Princeton, NJ, USA) 250 mg/m
2,f o l l o w e db y3
cycles of intensified CMF (cyclophosphamide 840 mg/m
2,
methotrexate 57 mg/m
2, fluorouracil 840 mg/m
2) (E-T-
CMF, experimental arm) or four cycles of epirubicin fol-
lowed by 4 cycles of CMF (E-CMF, control arm), at the
same doses as in the E-T-CMF arm. All cycles were given
every 2 weeks with G-CSF support. The results of the
HE10/97 have previously been published [17].
The clinical protocol and the related translational
research studies were approved by the HeCOG Protocol
Review Committee and by the Institutional Review
Boards of ‘’Kyanous Stavros’’ and ‘’AHEPA’’ Hospitals
and were carried out in compliance with the Helsinki
Declaration. The trial was included in the Australian
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allocated the following Registration Number:
ACTRN12611000506998. Upon participation in the trial,
all patients provided a written informed consent for
molecular studies of their tumor specimen.
Paraffin sections were histologically evaluated for
tumor adequacy and for tumor cell content. Where pos-
sible, tissue microarray (TMA) blocks were constructed
as previously described [19-21] with a manual arrayer
(Model I, Beecher Instruments, Sun Prairie, WI), includ-
ing two 1.5 mm cores per tumor and multiple neoplastic
and non-neoplastic tissue samples as controls for slide-
based assays. A REMARK diagram for the translational
research studies is provided in Figure 1.
Chromogenic in situ hybridization (CISH)
CISH was performed on all available tissue sections
(TMA or whole sections) by using SPoT-Light probes
from ZYMED™ (Invitrogen, Carlsbad, CA) for the
HER2 gene, TOP2A gene and Chromosome 17 centro-
meric region. The method was performed as described
by the manufacturer, with slight modifications, on three
separate slides, one for each probe. The specimens were
classified, according to the number of gene hybridization
signals per nucleus in more than 50% of cancer cells of
the infiltrative tumor component, in one of five CISH
ranks: rank 1: monosomy, if one signal per nucleus was
counted using the Chromosome 17 centromeric probe;
rank 2: diploid, with two signals per nucleus; rank 3:
polysomy, if tumor nuclei contained 3 to 5 signals using
the Chromosome 17 centromeric probe or if a very low
gene amplification with 3 to 5 gene copies per nucleus
was identified in diploid Chromosome 17 neoplastic
cells; rank 4: low gene amplification, if 6-10 signals or
small clusters were counted per nucleus; rank 5: high
gene amplification, if > 10 signals or large clusters were
detected per nucleus. CISH was considered positive for
amplification at ranks 4 and 5 [22,23].
595 eligible patients included in the clinical trial 
FFPE tissue samples available:  
n = 367 (62% of the patients) 
At least one value for HER2 or TOP2A available:  
n = 352 (96% of the FFPE blocks) 
Profiled HER2 variables 
HER2 CISH/mRNA n=249 (70%) 
HER2 CISH/IHC n=278 (79%) 
HER2 mRNA/IHC n=261 (74%) 
HER2, all n=243 (69%) 
Profiled TOP2A variables 
TOP2A CISH/mRNA n=232 (66%) 
TOP2A CISH/IHC n=249 (70%) 
TOP2A mRNA/IHC n=240 (68%) 
TOP2A, all n=217 (62%) 
Insufficient tumor tissue on sections 
Template abundance, method eligibility 
criteria 
CISH analysis 
HER2 n=285 (81%) 
TOP2A n=266 (76%) 
HER2/TOP2A n=266 (76%) 
qRT-PCR (mRNA expression) 
HER2 n=314 (89%) 
TOP2A n=314 (89%) 
HER2/TOP2A n=314 (89%) 
IHC analysis 
HER2 n=297 (84%) 
TopoIIa n=273 (78%) 
HER2/TopoIIa n=269 (76%) 
Figure 1 REMARK diagram detailing FFPE tissue and sample availability in the present study for the application of different analytical
techniques for the determination of HER2 and TOP2A gene status, mRNA and protein expression. The rates in parentheses for CISH, qRT-
PCR and IHC were calculated against the number of tissue samples with at least one HER2 or TOP2A value available (n = 352).
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RNA extraction was performed from whole or macrodis-
sected 10 μm paraffin sections at the Molecular Research
Laboratory of Siemens Healthcare Diagnostics (Cologne,
Germany), by using a fully automated isolation method
for total RNA, based on silica-coated magnetic beads
(Versant Tissue Preparation Reagents, Siemens Health-
care Diagnostics, Tarrytown, NY) in combination with a
liquid handling robot, as previously described in detail
[24,25]. In brief, this type of dual nuclear acid extraction
with silica coated magnetic beads involves an extra step
of DNase I digestion ensuring the presence of pure RNA
and the absence of DNA in the sample and yields mole-
cular templates of adequate quality from FFPE sections
for the assessment of gene expression with quantitative
real-time PCR. The tumor cell content of the FFPE sec-
tions used for the RNA extraction was > 30% in practi-
cally all (97%) of the samples, and > 50% in the majority
(76%) of the samples.
RNA samples were assessed by quantitative one-step
reverse transcription-PCR (qRT-PCR) with FAM-
TAMRA labelled Taqman assays for the relative expres-
sion of ERBB2 and TOP2A genes. RPL37A expression
(ribosomal protein L37a) was assessed for sample nor-
malization and for the evaluation of RNA content. For-
ward and reverse primers, probes, amplicon length,
location according to the coding NCBI reference
sequence, as well as percentage of PCR efficiency [E = 1
(10-slope)]f o re a c ha s s a yw e r ea sf o l l o w s( d a t ai nt h e
same order): for ERBB2,5 ’-CCAGCCTTCGA-
CAACCTCTATT-3’,5 ’-TGCCGTAGGTGTCCCTTTG-
3’,5 ’-FAM-ACCAGGACCCACCAGAGCGGG-
TAMRA-3’, 87 bp, exon 27 (NM_004448.2 and all
ERBB2 variants), 95.7%; for TOP2A,5 ’- CATTGAA-
GACGCTTCGTTATGG-3’,5 ’- CCAGTTGTGATGGA-
TAAAATTAATCAG-3’,5 ’-FAM-CAGATCAGGAC
CAAGATGGTTCCCACAT-TAMRA-3’, 104 bp, exons
13-14 (NM_001067.3), 85.2%; for RPL37A,5 ’-TG
TGGTTCCTGCATGAAGACA-3’,5 ’-GTGACAGCG-
GAAGTGGTATTGTAC-3’,5 ’-FAM-TGGCTGGCGG
TGCCTGGA-TAMRA-3’,6 5b p ,e x o n s3 - 4
(NM_000998.4), 86.0%. Reverse transcription real-time
quantitative PCR was performed with the SuperScript
®
III Platinum
® One-Step Quantitative RT-PCR System
with ROX (Invitrogen, Karlsruhe, Germany) according
to the manufacturer’s instructions. Experiments were
accomplished in an ABI PRISM
® 7900HT system
(Applied Biosystems, Darmstadt, Germany) with 30
min at 50°C and 2 min at 95°C followed by 40 cycles
of 15 s at 95°C, and 30 s at 60°C, as previously
described in detail [26]. Samples were run in triplicates
and were considered eligible for analysis when RPL37A
CT (cycle threshold) values were < 32 (triplicate mean
values). Relative expression levels of the target genes
were calculated as 40-dCT (i.e., 40-[CTtarget-CTRPL37A])
to yield positively correlated numbers and facilitate
comparisons.
Immunohistochemistry
Immunohistochemical methodology was employed for
the assessment of classic breast cancer protein mar-
kers, i.e., estrogen receptor alpha (ER), progesterone
receptor (PgR) and HER2, as well as of the prolifera-
tion marker Ki67 and topoisomerase II-alpha
(TopoIIa). Immunohistochemical staining was per-
formed according to standard protocols, with slight
modifications, on serial 2.5 μm thick sections from the
TMA blocks using the Bond Max™ (Leica Microsys-
tems, Germany/Menarini Diagnostics, Athens, Greece)
and i6000 (Biogenex, San Ramon, CA) autostainers. To
assure optimal reactivity, immunostaining was applied
within a period of 3-10 days after sectioning. Where
possible, non-informative cases, as well cases not
embedded on TMAs were re-cut from the original
blocks and used for protein and gene analysis. Immu-
nohistochemical evaluation was based on established
or proposed criteria [23,27-29]. The methods employed
for each marker (antibodies and processing conditions)
as well as the evaluation criteria for each protein target
a r es h o w ni nT a b l e1 .
Table 1 Proteins, source and dilution of antibodies, staining procedures and patterns and interpretation of results
Protein Antibody [clone,
source]
Ab
dilution
Pretreatment/
EU
IT IHC Staining Detection System/
Chromogen
Scoring
System
Cut-off
(%)
Staining
Pattern
Reference
Ki67 MIB1 (1) 1:70 15’/EU2 20’ Polymer HRP/DAB SQ ≥ 14%* Nuclear [28]
HER2 PL (1) 1:200 25’/EU1 30’ Polymer HRP/DAB 0-3 > 30%
# Membranous [23]
TopoIIa KiS1 (1) 1:200 15’/EU2 30’ EnVision/DAB SQ > 5%** Nuclear [27]
ER 6F11 (2) 1:70 20’/EU1 20’ Polymer HRP/DAB H-Score ≥ 1% Nuclear [29]
PgR 1A6 (2) 1:70 20’/EU1 20’ Polymer HRP/DAB H-Score ≥ 1% Nuclear [29]
Antigen Retrieval was done on a hot plate at 98°C.
DAB: 3,3’-Diaminobenzidine; EU: Epitope Unmasking; EU1: Citric acid, pH 6.0; EU2: Ethylenediaminetetraacetate, pH 8.8; HRP: Horseradish Peroxidase; IT:
Incubation time; SQ: Semiquantitative.
(1): Dako, Glostrup, Denmark; (2): Leica Biosystems, Newcastle Upon Tyne, UK.
*: Proliferation Index: Low if < 14% and High if ≥14% positive nuclei were observed; #: score 3+ in cases with > 30% positive tumor cells; **: positive if at least
moderate staining intensity in > 5% of tumor cells.
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Categorical data are presented as numbers and corre-
sponding percentages, while continuous data are pre-
sented as median and range values. The Fisher’s exact
test or Pearson chi-square were used for group compari-
son of categorical data, while for continuous data the
Mann-Whitney test was used. Distributional cut-offs
were used to categorize tumors into low and high HER2
and TOP2A mRNA expression.
DFS was defined as the time interval from study entry
to first locoregional recurrence, first distant metastasis,
contralateral breast cancer, secondary neoplasm, death
from the disease, or death from any cause non-related
to breast cancer, whichever occurred first [30]. OS was
measured from study entry until death from any cause.
Surviving patients were censored at the date of last
contact.
Kaplan-Meier curves and log-rank tests were used for
comparing time to event distributions. Cox proportional
hazard regression analyses, adjusted for treatment, were
performed for the examined markers, as well as for the
combination of HER2/TOP2A variables (HER2/TOP2A
gene amplification, high HER2/TOP2A mRNA expression,
HER2/TopoIIa protein positivity) to assess prognostic sig-
nificance on OS and DFS. In multivariate analysis, a back-
ward selection procedure with p > 0.10 as a removal
criterion based on the likelihood ratio test was performed
to identify significant clinicopathological variables among
the following: age, treatment group (E-CMF vs. E-T-
CMF), menopausal status (postmenopausal vs. premeno-
pausal), tumor grade (III-undifferentiated vs. I-II), Ki67
protein expression (high vs. low), tumor size (> 5 cm vs. 2
to 5 cm vs. < 2 cm), number of positive axillary nodes (≥ 4
vs. 0-3), ER/PgR status (positive vs. negative), adjuvant
hormonotherapy (yes vs. no), adjuvant radiotherapy (yes
vs. no), type of operation (breast conserving surgery vs.
modified radical mastectomy) and time interval from
breast surgery operation (> 4 weeks vs. 2-4 weeks vs. < 2
weeks). Treatment group and the examined markers (or
the combination of HER2/TOP2A) were entered in the
final model, in order to examine whether they added inde-
pendent prognostic information to the model containing
the significant clinicopathological parameters.
The results of this study are presented according to
reporting recommendations for tumor marker prognos-
tic studies [31]. This study is prospective-retrospective
as previously described [32]. The SPSS software was
used for statistical analysis (SPSS for Windows, version
15.0, SPSS Inc.).
Results
Patient and Tumor Characteristics
In total 352 patients were included in the present analy-
sis. Slightly more patients received adjuvant E-CMF
chemotherapy (N = 193) than with E-T-CMF (N = 159).
The majority of cases underwent modified radical mas-
tectomy (78%) and had four or more involved nodes
(75%). Most of the carcinomas were hormone-receptor
positive (79%) and they also expressed high Ki67 (82%).
With the exception of high tumor grade and HER2 pro-
tein overexpression, which were more common in the
E-T-CMF arm, basic clinicopathological characteristics
were well balanced when the 352 analyzed patients were
stratified by adjuvant chemotherapy arm (Table 2). The
unbalance of tumor grade in the two treatment arms
had been reported in the randomized study [17]. After a
median follow-up time of 98 months (range: 7.0-126.3),
125 patients (36%) had developed a documented disease
relapse and 93 patients (26%) died. 5-year DFS and OS
(E-CMF vs. E-T-CMF) was 68.7% vs. 72.1% (Hazard
ratio [HR] = 1.12, 95% Confidence interval [CI]: 0.76-
1.66, Wald’s p = 0.56) and 5-year OS was 81.2% vs.
85.5% (HR = 1.31, 95% CI: 0.78-2.22, Wald’s p = 0.31).
HER2 and TOP2A gene status, mRNA and protein
expression
CISH analysis for HER2 was informative in 285 cases
(Figure 1, Table 2) with representative examples shown
in Figure 2A and 2B. HER2 gene amplification (low and
high) was observed in 64 cases (22.5%). Polysomy with 3
to 5 signals was observed in 60 cases, while the rest 161
cases were diploid. Relative quantification (RQ) of HER2
mRNA expression was informative in 314 cases. The
distribution of HER2 RQ values was bimodal (Figure
3A) and thus the 75
th percentile (37.41 arbitrary units)
was used to classify HER2-low and HER2-high expres-
sing tumors, since it was close to the natural cut-off.
IHC analysis for HER2 was applicable in 297 cases (Fig-
ure 1, 2E and 2F) with the majority of cases (71%)
scored as HER2 0-1+, 17.5% as 3+, and 11% as 2+
(Table 2).
HER2 gene amplification was significantly associated
with HER2 immunostaining (p < 0.001), with only two
HER2 non-amplified tumors showing 3+ staining for the
corresponding protein, which proves the strong associa-
tion between HER2 gene amplification and protein over-
expression. Increased HER2 mRNA expression was
f o u n ds i g n i f i c a n t l ym o r ef r e q u e n ti nI H Cg r a d e3
tumors (Figure 4A) and was also associated with HER2
gene amplification Figure 4B). The same significance
was obtained for binary high HER2 mRNA with IHC
and with HER2 gene status (Fisher’se x a c tt e s tp<
0.001).
CISH, mRNA RQ values and IHC results for TOP2A
were informative in 266, 314 and 273 cases, respectively
(Figure 1, Table 2). Representative examples for TOP2A
gene status with CISH are shown in Figure 2C and 2D.
TOP2A gene amplification was observed in 19 cases
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E-T-CMF E-CMF Analyzed cohort
(N = 159) (N = 193) (N = 352)
Median Range Median Range Median Range
Age (in years) 50.2 23.8-75.9 50.6 22.5-78.0 50.6 22.5-78.0
Number of nodes removed 19 5-59 19 4-53 19 4-59
Number of positive nodes 7 0-54 6 0-49 6 0-54
N%N%N%
Nodal involvement (n = 352)
0-3 nodes 34 21.4 54 28.0 88 25.0
≥ 4 nodes 125 78.6 139 72.0 264 75.0
Menopausal status (n = 352)
Premenopausal 83 52.2 104 53.9 187 53.1
Postmenopausal 76 47.8 89 46.1 165 46.9
Type of operation (n = 352)
Modified radical mastectomy 122 76.7 151 78.2 273 77.6
Breast conserving surgery 37 23.3 42 21.8 79 22.4
Interval from operation (n = 352)
< 2 weeks 19 11.9 26 13.5 45 12.8
2-4 weeks 81 50.9 84 43.5 165 46.9
> 4 weeks 59 37.1 83 43.0 142 40.3
Tumor grade* (n = 351)
I-II 64 40.5 112 58.0 176 50.1
III-Undifferentiated 94 59.5 81 42.0 175 49.9
Tumor size (n = 352)
< 2 cm 45 28.3 67 34.7 112 31.8
2-5 cm 88 55.3 91 47.2 179 50.9
> 5 cm 26 16.4 35 18.1 61 17.3
Adjuvant RT (n = 350)
No 27 17.1 39 20.3 66 18.9
Yes 131 82.9 153 79.7 284 81.1
Adjuvant HT (n = 351)
No 12 7.6 21 10.9 33 9.4
Yes 146 92.4 172 89.1 318 90.6
ER protein status (n = 306)
Negative 40 28.2 41 25.0 81 26.5
Positive 102 71.8 123 75.0 225 73.5
PgR protein status (n = 305)
Negative 52 36.6 54 33.1 106 34.8
Positive 90 63.4 109 66.9 199 65.2
Hormone receptor status (n = 307)
Negative 36 25.4 29 17.6 65 21.2
Positive 106 74.6 136 82.4 242 78.8
Ki67 (n = 309)
Low (< 14%) 25 17.4 30 18.2 55 17.8
High (≥ 14%) 119 82.6 135 81.8 254 82.2
HER2 CISH amplification (n = 285)
Non-amplified 100 75.2 121 79.6 221 77.5
Amplified 33 24.8 31 20.4 64 22.5
HER2 mRNA expression (n = 314)
Low (< 75
th percentile) 108 75.0 128 75.3 236 75.2
High (≥ 75
th percentile) 36 25.0 42 24.7 78 24.8
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amplification). TOP2A polysomy was seen in 51 cases
(19%). No deletions were identified. In contrast to
HER2, TOP2A mRNA expression had a unimodal distri-
bution (Figure 3B) and thus the median cut-off (33.38
arbitrary units) was used to classify low and high
TOP2A mRNA expression. Positive TopoIIa protein
immunostaining was observed in 64% of the cases
(Table 2). Representative examples of TopoIIa IHC are
shown in Figure 2G and 2H.
TOP2A gene amplification was not associated with
TopoIIa protein status (p = 0.80), since the majority
(92%) of TopoIIa protein positive tumors were TOP2A
non-amplified and IHC positivity rates did not differ in
amplified and non-amplified tumors. Increased TOP2A
mRNA expression, both as a continuous (Figure 4C)
and as a binary variable, was strongly associated with
positive TopoIIa IHC status (Fisher’se x a c tt e s t ,p<
0.001 for the binary comparison). By contrast, TOP2A
mRNA expression was not associated with TOP2A gene
amplification (Figure 4D and Fisher’se x a c tt e s tp=
0.395 for the binary comparison). Only one TOP2A
amplified tumor exhibited a higher mRNA RQ value in
comparison to non-amplified tumors.
Association between HER2 and TOP2A parameters
TOP2A gene status was strongly associated with HER2
gene status (Fisher’s exact test, p < 0.001). Co-amplifica-
tion of HER2 and TOP2A genes was observed in 13 out
of 282 informative tumors (4.6%) and in 13/61 HER2
positive tumors informative for TOP2A (21.3%). TOP2A
amplification without HER2 amplification was observed
in 6 cases (31.6% of all TOP2A amplified cases, 2.3%
among all informative tumors for both HER2 and
TOP2A). Upon revisiting these six cases, four displayed
very low HER2 gene amplification (3 to 5 copies per
nucleus), while 3 of them were also centromere 17 poly-
somic. According to current guidelines for assessing
HER2 amplification with CISH [23], these cases had
been correctly characterized as HER2 non-amplified;
however, they did contain an increased number of
HER2 copies. Hence, only two cases in our series
remained as unequivocally low amplified for TOP2A
with diploid HER2 and centromere 17 (0.8% among all
informative tumors or 10% among TOP2A amplified
tumors). Such rates have previously been reported for
TOP2A amplification in the absence of HER2 amplifica-
tion, when tested with FISH [33].
When compared in a continuous scale, mRNA expres-
sion of both genes exhibited a significant, although line-
arly weak correlation (Rho = 0.23, p < 0.001). However,
when examined as binary variables (high/low mRNA
expression), HER2 and TOP2A RNA expression were
not associated (Fisher’s exact test, p = 0.36). Among the
314 cases with informative mRNA results for both
HER2 and TOP2A, 43 cases (13.7%) expressed both
genes at high levels.
Among the HER2 IHC positive cases, 66% were also
TopoIIa protein positive, while among all tumors infor-
mative for IHC, 33 cases were HER2 and TopoIIa posi-
tive (9.4%). Hence, the overall association of TopoIIa
with HER2 protein positivity was not significant (Fisher’s
exact test, p = 0.75).
HER2 and TOP2A profiles for the 214 tumors infor-
mative for all above parameters (61% of the entire
tumor series) are shown in Figure 5.
Association of HER2 and TOP2A with clinicopathological
parameters
Patient age, menopausal status and lymph node involve-
ment were not associated with HER2 and TOP2A para-
meters in the cohort examined. High-grade tumors
Table 2 Selective patient and tumor characteristics (Continued)
HER2 protein expression (n = 297)**
0-1+ 86 63.2 125 77.6 211 71.0
2+ 19 14.0 15 9.3 34 11.4
3+ 31 22.8 21 13.0 52 17.5
TOP2A CISH amplification (n = 266)
Non-amplified 110 90.9 137 94.5 247 92.9
Amplified 11 9.1 8 5.5 19 7.1
TOP2A mRNA expression (n = 314)
Low (< median) 72 50.0 85 50.0 157 50.0
High (≥ median) 72 50.0 85 50.0 157 50.0
TopoIIa protein status (n = 273)
Negative 43 35.2 56 37.1 99 36.3
Positive 79 64.8 95 62.9 174 63.7
*: p = 0.001; **: p = 0.023; The distribution of grade and HER2 protein expression differs significantly between the two groups.
RT. radiotherapy; HT. hormonotherapy; CISH. chromogenic in situ hybridization.
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Page 7 of 21Figure 2 Representative examples of HER2 and TopoIIa protein expression and corresponding gene status. A-D: immunohistochemistry
at a magnification of 100Χ (A: HER2 3+, B: HER2 0, C: TopoIIa positive and D: TopoIIa negative). E-H: CISH at a magnification of 600Χ (E: HER2
positive/amplified, F: HER2 negative/diploid, G: TOP2A positive and H: TOP2A negative).
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Page 8 of 21expressed higher levels of HER2 and TOP2A mRNA (p
= 0.001 and p = 0.002, respectively) in comparison to
lower grade tumors. In addition, although HER2 3+
tumors were more often of high grade, this feature did
not reach statistical significance (p = 0.066), but signifi-
cantly more high-grade tumors were positive for
TopoIIa protein (p < 0.001). TOP2A gene amplification
occurred independently of tumor grade. Further,
TOP2A gene amplification was preferably observed in
tumors > 2 cm (16/19 amplified cases [84%], p = 0.085);
similarly, HER2 protein positivity occurred more often
in tumors > 2 cm (p = 0.078).
Associations of HER2 and TOP2A parameters with ER
and PgR status, as well as with Ki67 scores are pre-
sented in Table 3. HER2 3+ tumors significantly more
often exhibited negative ER status, negative PgR status,
and Ki67 score ≥ 14%. Similar results were obtained for
HER2 amplification with CISH in comparison to the
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B 
Figure 3 Distribution of relative mRNA expression (40-dCT values) for A) HER2 (median: 36.02, 25th percentile: 35.20, 75th percentile:
37.41) and B) TOP2A (median: 33.38, 25th percentile: 32.46, 75th percentile: 34.18). Red lines represent the cut-offs used (75th percentile
for HER2 and median for TOP2A).
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Page 9 of 21same markers, as well as for HER2 mRNA expression
regarding ER and PgR status. Regarding TOP2A,
TopoIIa protein positivity and high TOP2A mRNA
expression were significantly associated with high Ki67
labeling. No association was found for these parameters,
as well as for TOP2A gene amplification with ER and
PgR tumor status.
Prognostic/predictive significance of HER2 and TOP2A
Univariate Cox regression analysis (Table 4), adjusted
for paclitaxel treatment, revealed increased risk of
relapse for HER2 IHC grade 3+ in comparison to 0 or 1
+ tumors, as well as for tumors with HER2 gene ampli-
fication in comparison to non-amplified tumors. Since
we performed IHC and CISH analysis, we also examined
the prognostic significance of the combination for the
two methods. Thus, we introduced a HER2 status vari-
able considering IHC 3+ and/or CISH amplified tumors
as HER2 positive; it should be noted however, that for
12 of the 297 patients with HER2 IHC data, CISH data
were not available. The remaining patients were
considered as HER2 negative. Again, positive HER2 sta-
tus was associated with increased risk for relapse in
comparison to negative HER2 status (Table 4, Figure
6A). In addition, high HER2 mRNA expression was
strongly associated with shorter DFS (Table 4, Figure
6C). Among TOP2A parameters, increased risk for
relapse was only observed for tumors with high TOP2A
mRNA expression as compared to tumors expressing
low TOP2A (Figure 6E). In terms of OS, HER2 IHC 3+
score was associated with increased risk for death, while
IHC 2+ tumors also performed worse as compared to 0
or 1+ tumors. HER2 gene status by CISH was margin-
ally not associated with OS, while HER2 IHC positive
tumors and tumors expressing high HER2 mRNA
expression were also associated with increased risk for
death (Figure 6B and 6D). High TOP2A mRNA expres-
sion was strongly adversely associated with survival
(Table 4, Figure 6F). In order to examine the predictive
significance of HER2 and TOP2A expression we tested
the interaction with paclitaxel treatment but no such
association was found (Wald’s p > 0.05 in all tests).
Figure 4 Association of HER2 and TOP2A relative mRNA expression (40-dCT values) with corresponding protein expression by IHC (A,
B) and gene amplification by CISH (C, D). Comparisons were made using Kruskal Wallis and Mann-Whitney tests.
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Figure 5 HER2 and TOP2A profiling for gene status, RNA and protein expression in adjuvantly treated breast carcinomas. Green cells:
non-amplified, low mRNA expression, negative protein expression; Red cells: gene amplification, high mRNA expression, protein positivity. HER2
mRNA and protein expression exhibit different positivity patterns in comparison to TOP2A mRNA and TopoIIa protein expression. The majority of
tumors with high TOP2A mRNA expression (112/121 [95.6%]) and the majority of tumors positive for TopoIIa protein expression (145/158 [91.8%])
were not amplified.
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Page 11 of 21We next analyzed combined qualitative positivity of
HER2/TOP2A variables at the same molecular level
(HER2/TOP2A gene amplification, HER2/TOP2A high
mRNA as a binary variable, HER2 3+/TopoIIa protein
positivity). This approach revealed that patients with
tumors expressing both HER2/TOP2A high mRNA,
and to a lesser extent, positive for both HER2/TopoIIa
proteins had a significantly worse outcome than
patients with all other combinations of these two para-
meters (both low or low/high for mRNA; both negative
or negative/positive for protein) (Table 4). Forty-three
patients with high HER2/TOP2A mRNA expression
had a higher risk for relapse and death in comparison
to patients with tumors expressing all other combina-
t i o n so fH E R 2 / T O P 2 Am R N Ae x p r e s s i o n( F i g u r e7 A
and 7B). Patients with tumors positive for both HER2
and TopoIIa proteins (n = 33) were in higher risk for
relapse and death in comparison to patients with
tumors exhibiting all other patterns of HER2/TopoIIa
IHC status (Figure 7C and 7D). Finally, patients with
tumors carrying HER2/TOP2A co-amplification
showed a trend for favorable disease-free survival in
comparison to tumors where only one or none of the
two genes was amplified. It must be noticed that
HER2/TOP2A co-amplified tumors in this study con-
cerned 13 patients only, of which only one relapsed at
1 8m o n t h sa n dd i e do fd i s ease at 48 months, while no
other events were noted during the entire follow-up
period (101.2 months).
In the multivariate analysis we first examined the
prognostic significance of single HER2 and TOP2A
parameters adjusted for significant clinicopathological
variables (Table 5). Among HER2 variables, only HER2
mRNA expression remained significant for both DFS
and OS, with tumors expressing high mRNA levels hav-
ing increased risk for relapse and death, as compared to
low HER2 mRNA tumors. Among the three parameters
examined for TOP2A, gene amplification was associated
with longer DFS, while tumors with high TOP2A
mRNA expression had shorter survival. These findings
may appear as discrepant but in fact they are not,
because most of the tumors with high TOP2A mRNA
expression were not TOP2A amplified (Figure 5), while
only 9/19 TOP2A amplified tumors expressed high
TOP2A RNA. Thus, TOP2A amplified and high TOP2A
mRNA tumors correspond to distinct groups of patients
with minimal overlap, especially with respect to the sec-
ond category. In the final model we included the signifi-
cant predictors for DFS and OS (mRNA expression for
HER2 and TOP2A, and CISH gene status for TOP2A)
and found that only HER2 mRNA expression was a sig-
nificant adverse prognostic factor for both DFS and OS,
while TOP2A mRNA expression was significant only for
OS. In this model, nodal involvement and hormonal sta-
tus, as well as Ki67 labeling remained significant in pre-
dicting patient DFS and OS.
The same approach of multivariate analysis was
applied for the combined HER2/TOP2A variables (Table
Table 3 Associations of HER2 and TOP2A with ER, PgR and Ki67 status (assessed by IHC)
ER status PgR status Ki67 status
Negative Positive p Negative Positive p Low High p
N (%) N (%) N (%) N (%) N (%) N (%)
HER2 (CISH) < 0.001 0.001 0.035
Non-amplified 47 (61.8) 173 (83.2) 63 (65.6) 156 (83.4) 42 (89.4) 176 (75.2)
Amplified 29 (38.2) 35 (16.8) 33 (34.4) 31 (16.6) 5 (10.6) 58 (24.8)
HER2 (mRNA) < 0.001 < 0.001 0.086
Low (< 75
th perc) 38 (55.9) 166 (82.6) 53 (59.6) 151 (84.4) 40 (87.0) 168 (74.0)
High (≥ 75
th perc) 30 (44.1) 35 (17.4) 36 (40.4) 28 (15.6) 6 (13.0) 59 (26.0)
HER2 (IHC) 0.003 0.002 0.016
0-1+ 47 (58.8) 163 (75.5) 61 (58.7) 148 (77.5) 43 (87.8) 163 (67.4)
2+ 9 (11.3) 25 (11.6) 15 (14.4) 19 (9.9) 3 (6.1) 31 (12.8)
3+ 24 (30.0) 28 (13.0) 28 (26.9) 24 (12.6) 3 (6.1) 48 (19.8)
TOP2A (CISH) 0.29 0.46 0.33
Non-amplified 64 (90.1) 182 (93.8) 83 (91.2) 162 (93.6) 41 (97.6) 202 (91.8)
Amplified 7 (9.9) 12 (6.2) 8 (8.6) 11 (6.4) 1 (2.4) 18 (8.2)
TOP2A (mRNA) 0.99 0.20 0.003
Low (< median) 34 (50.0) 100 (49.8) 39 (43.8) 94 (52.5) 33 (71.7) 107 (47.1)
High (≥ median) 34 (50.0) 101 (50.2) 50 (56.2) 85 (47.5) 13 (28.3) 120 (52.9)
TopoIIa (IHC) 0.39 0.99 < 0.001
Negative 29 (40.3) 69 (34.5) 33 (35.9) 64 (35.8) 32 (78.0) 66 (28.8)
Positive 43 (59.7) 131 (65.5) 59 (64.1) 115 (64.2) 9 (22.0) 163 (71.2)
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HER2/TopoIIa protein co-expression were significant
for DFS but not for OS, while high HER2/TOP2A
mRNA co-expression was strongly adversely significant
for both DFS and OS. When the analysis was adjusted
for all combined parameters along with classic clinico-
pathological variables (nodal involvement, hormone
receptor status and Ki67 labeling), high HER2/TOP2A
mRNA co-expression remained strongly significant as
an unfavorable prognostic factor for both DFS and OS,
while HER2/TOP2A gene co-amplification remained sig-
nificant as a favorable prognostic factor for OS only.
Again, throughout the applied models, hormone recep-
tor status was a favorable, while the number of involved
lymph nodes and high Ki67 protein expression were
unfavorable independent predictors of patient outcome.
Discussion
Even though the adverse prognostic role of HER2 para-
meters (gene amplification and mRNA and protein over-
expression) in patients with operable breast cancer is
indisputable, that of TOP2A parameters remains contro-
versial. Moreover, the optimal parameter(s) and respec-
tive methodologies for assessing HER2 [23,34,35] and
TOP2A [7,36] status are still not well defined. Concern-
ing methods, in this study we employed CISH for the
assessment of HER2 and TOP2A gene status. CISH is
an accepted method for the evaluation of the HER2
gene [23] but it should be noticed that, while CISH and
FISH results are highly concordant in true negative
(diploid) and highly amplified tumors, the two methods
yield discordant results in cases with low HER2 amplifi-
cation [37]. Further, CISH is not the method for
Table 4 Univariate Cox regression analysis for HER2 and TOP2A adjusted for treatment
Disease-free survival Overall survival
HR 95% C.I. Wald’s p HR 95% C.I. Wald’sp
HER2 (CISH)
Non-amplified 1 1
Amplified 1.55 1.01-2.39 0.045 1.62 0.98-2.66 0.060
HER2 (mRNA)
Low 1 1
High 1.89 1.29-2.79 0.001 1.91 1.21-3.02 0.005
HER2 (IHC)
0-1+ 1 1
2+ 1.61 0.93-2.78 0.091 2.13 1.18-3.84 0.012
3+ 1.75 1.10-2.79 0.019 1.78 1.02-3.08 0.041
HER2 status
Negative 1 1
Positive* 1.57 1.04-2.39 0.033 1.68 1.04-2.72 0.034
TOP2A (CISH)
Non-amplified 1 1
Amplified 0.35 0.11-1.10 0.072 0.34 0.08-1.38 0.131
TOP2A (mRNA)
Low 1 1
High 1.45 1.01-2.10 0.046 2.34 1.46-3.73 < 0.001
TopoIIa (IHC)
Negative 1 1
Positive 1.37 0.90-2.10 0.145 1.55 0.93-2.60 0.094
HER2/TOP2A CISH
All other 1 1
Both amplified 0.17 0.2-1.20 0.075 0.25 0.04-1.80 0.17
HER2/TOP2A mRNA
All other 1 1
Both high 2.15 1.37-3.38 0.001 2.51 1.51-4.18 < 0.001
HER2/TopoIIa IHC
All other 1 1
Both positive 1.92 1.14-3.25 0.015 1.89 1.04-3.44 0.038
* IHC 3+ or CISH amplified.
There was no interaction between examined markers with treatment regimens (p > 0.05 for all interaction tests).
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Page 13 of 21reporting gene deletions [16,38], hence we did not regis-
ter any TOP2A deletions like those reported with FISH
[33,39-41]. In terms of TOP2A gene amplification, the
incidence with CISH in our cohort (7%) was low but
still comparable to previous reports assessing this para-
meter with FISH [33,42],. while TOP2A amplified/HER2
non-amplified tumors have also been reported with
FISH [33]. It seems that, concerning the amplification
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Figure 6 Impact of HER2 gene amplification and HER2 and TOP2A mRNA expression on patient outcome. Kaplan-Meier curves for HER2
status (A, B), HER2 mRNA expression (C, D) and TOP2A mRNA expression (E, F) in terms of disease-free (DFS) and overall survival (OS).
Comparisons by log-rank test. Red lines: positive or high; Blue lines: negative or low.
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Page 14 of 21part of TOP2A gene pathology, CISH results may be
considered comparable with the much more abundant
FISH results in the literature.
It is noteworthy that information in the literature
regarding a thorough evaluation of both HER2 and
TOP2A at all levels of molecular pathology (gene, RNA,
protein) is very limited. To our knowledge the present
study is one of the few attempting to define the relation-
ship between TOP2A gene copy numbers with TOP2A
RNA and TopoIIa protein expression and possibly the
first in the context of an adjuvant phase III trial includ-
ing patients with breast cancer treated with anthracy-
clines. In a report by Brase et al [36], the prognostic
relevance of the HER2 and TOP2A genes was compre-
hensively studied at the DNA, RNA and protein level in
three independent patient cohorts. It is of interest, that
although this report differs from ours substantially in
terms of design, patient population and treatment, both
studies share a considerable number of common find-
ings. In the Brase et al study [36], high TOP2A RNA
levels were significantly associated with shorter metasta-
sis-free survival in node-negative (low-risk) patients who
did not receive adjuvant chemotherapy, but the same
parameter seemed to be associated with better response
to anthracyclines. In the present study, all patients had
received epirubicin; in this “anthracycline-treatment
homogeneous” population, where the parameter “anthra-
cyclines” may be eliminated, high TOP2A mRNA
expression was an adverse prognostic parameter for
patient OS, a function that remained significant after
A  B 
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Figure 7 Impact of combined HER2 and TOP2A (HER2/TOP2A) parameters on patient outcome. Kaplan-Meier curves for combined HER2/
TOP2A mRNA expression (A, B) and combined HER2/TopoIIa protein status (C, D) in terms of DFS and OS. Comparisons by log-rank test. Red
lines: HER2/TOP2A high mRNA expression (A, B) or HER2/TopoIIa positive protein expression (C, D); Blue lines: all other combinations.
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Page 15 of 21adjustment for hormone receptor status, nodal involve-
ment, Ki67 labelling and HER2 status. Thus, the present
data support an unfavorable long-term prognostic role
for TOP2A mRNA expression in high-risk patients who
received adjuvant treatment.
I nc o n t r a s tt oT O P 2 Am R N Ae x p r e s s i o n ,T O P 2 A
gene amplification was independently associated with
prolonged DFS in our patients, in line with repeated
reports pointing out TOP2A gene amplification as a
marker predicting for response to anthracyclines
Table 5 Multivariate Cox regression analysis A) for HER2, B) for TOP2A and C) for both HER2 and TOP2A, adjusted for
significant clinicopathological parameters in terms of DFS and OS
Disease-free survival Overall survival
HR 95% C.I. Wald’s p HR 95% C.I. Wald’sp
A) Group
E-CMF vs E-T-CMF 1.07 0.72-1.59 0.75 1.58 0.96-2.60 0.071
Tumor size
2-5 cm vs < 2 cm 1.62 0.99-2.67 0.056
> 5 cm vs < 2 cm 1.73 0.92-3.22 0.087
Adjuvant HT
Yes vs No 0.50 0.27-0.94 0.031
Nodal involvement
≥ 4 vs 0-3 2.16 1.19-3.93 0.011 1.83 0.92-3.61 0.082
Hormone receptor status
Positive vs Negative 0.54 0.30-0.94 0.030
Ki67
High vs Low 1.69 0.91-3.15 0.096 3.54 1.27-9.84 0.015
HER2 (mRNA)
High vs Low 1.68 1.10-2.58 0.016 1.77 1.04-3.02 0.035
B) Group
E-CMF vs E-T-CMF 1.20 0.79-1.82 0.40 1.58 0.96-2.60 0.071
Nodal involvement
≥ 4 vs 0-3 3.03 1.56-5.85 0.001 2.21 1.11-4.38 0.024
Hormone receptor status
Positive vs Negative 0.49 0.31-0.78 0.003 0.42 0.24-0.71 0.001
Ki67
High vs Low 2.04 1.05-3.97 0.035 3.50 1.25-9.76 0.017
TOP2A (CISH)
Amplified vs Non-amplified 0.29 0.09-0.93 0.038
TOP2A (mRNA)
High vs Low 2.08 1.24-3.47 0.005
C) Group
E-CMF vs E-T-CMF 1.17 0.74-1.84 0.51 1.60 0.97-2.64 0.065
Nodal involvement
≥ 4 vs 0-3 2.82 1.39-5.71 0.004 2.09 1.05-4.16 0.036
Hormone receptor status
Positive vs Negative 0.56 0.33-0.96 0.035 0.49 0.28-0.86 0.014
Ki67
High vs Low 2.24 1.01-4.98 0.048 3.18 1.13-8.92 0.028
HER2 (mRNA)
High vs Low 1.80 1.10-2.93 0.019 1.73 1.02-2.93 0.040
TOP2A (CISH)
Amplified vs Non-amplified 0.36 0.11-1.17 0.091
TOP2A (mRNA)
High vs Low 1.52 0.97-2.41 0.070 2.06 1.23-3.46 0.006
HT, hormonotherapy
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Page 16 of 21[42-47]. Of note, since, as shown, tumors with TOP2A
gene amplification did not necessarily express high
T O P 2 Am R N Al e v e l sa n dvice versa, the analyzed
groups of patients with TOP2A gene amplification and
high TOP2A mRNA expression overlapped to a small
degree (8%) but certainly did not match. The effect of
TOP2A amplification on patient outcome depends on
the setting examined and seems relevant mainly in
HER2-positive tumors, as revealed in the largest series
tested so far for both HER2 and TOP2A gene amplifica-
tion [42]. The incidence of TOP2A-amplified tumors
within the HER2-positive group was relatively small in
the present study (21%), instead of the ~35% reported
by Press et al [42]. Even in this small group of patients,
HER2/TOP2A co-amplification was revealed as an inde-
pendent good prognostic factor for DFS in multivariate
analysis; since DFS is treatment-related, this favorable
prognostic value of HER2/TOP2A co-amplification
might be considered in line with the earlier described
positive predictive value of this marker for anthracy-
clines. Whether TOP2A itself or some other gene in the
same chromosomal region, which is also detected by the
large CISH/FISH probes, is responsible for the favour-
able prognostic value of HER2/TOP2A co-amplification
remains to be elucidated.
As discussed above, two different TOP2A parameters,
gene amplification and mRNA expression, seem to have
a distinct impact on the outcome of breast cancer
patients treated in the adjuvant setting. Although this
appears as a paradox, it is fully compatible with the
descriptive data presented in the present study concern-
ing associations among TOP2A parameters: TOP2A
mRNA and TopoIIa protein expression were strongly
associated with each other but largely unrelated to
TOP2A gene status. In comparison, all HER2 para-
meters (gene status, mRNA and protein expression)
were strongly interrelated in our series, in accordance to
most published data so far (comprehensively reviewed in
[48]). The lack of associations between TOP2A gene sta-
tus and TOP2A gene products (RNA and protein) has
repeatedly been reported [27,36,43,46,49-51] and does
not seem surprising considering key issues in TOP2A
regulation and function. There is increased demand for
TopoIIa protein during DNA replication [52], hence, the
corresponding gene is transcribed independently of the
existing copy numbers or of activated oncogenes [53].
In addition, TOP2A transcription may be strongly
downregulated by wild type p53 [54], or strongly upre-
gulated by HMGB1 and HMGB2 [55], while the half-life
of TOP2A mRNA may depend on redox-sensitive
Table 6 Multivariate Cox regression analysis A) for HER2/TOP2A co-amplification, B) for HER2/TOP2A mRNA
expression, C) for HER2/TopoIIa protein expression and D) for all combined HER2/TOP2A parameters, adjusted for
significant clinicopathological parameters in terms of DFS and OS
Disease-free survival Overall survival
HR 95% C.I. Wald’s p HR 95% C.I. Wald’sp
A) E-CMF vs E-T-CMF 1.26 0.85-1.88 0.25 1.67 1.03-1.72 0.038
Nodal involvement (≥ 4 vs 0-3) 3.53 1.82-6.85 < 0.001 2.96 2.96 0.004
Hormone receptor status (pos. vs neg.) 0.48 0.31-0.77 0.002 0.40 0.24-0.68 0.018
Ki-67 (high vs low) 1.97 1.06-3.65 0.031 2.77 1.19-6.46 0.018
HER2&TOP2A gene (both ampl. vs all other) 0.12 0.02-0.88 0.037 0.16 0.02-1.14 0.067
B) E-CMF vs E-T-CMF 1.16 0.77-1.75 0.47 1.56 0.95-2.57 0.079
Nodal involvement (≥ 4 vs 0-3) 2.67 1.44-4.93 0.002 2.07 1.05-4.09 0.035
Hormone receptor status (pos. vs neg.) 0.57 0.36-0.91 0.018 0.48 0.28-0.83 0.008
Ki67 (high vs low) 1.92 0.98-3.77 0.057 3.40 1.22-9.48 0.019
HER2&TOP2A mRNA (high vs low) 2.30 1.39-3.81 0.001 2.48 1.41-4.36 0.002
C) E-CMF vs E-T-CMF 1.18 0.80-1.74 0.39 1.62 1.02-2.57 0.042
Nodal involvement (≥ 4 vs 0-3) 3.00 1.64-5.49 < 0.001 2.43 1.25-4.73 0.009
Hormone receptor status (pos. vs neg.) 0.64 0.41-0.99 0.047 0.51 0.31-0.85 0.009
Ki67 (high vs low) 1.68 0.93-3.05 0.086 2.27 1.03-5.00 0.041
HER2&TopoIIa IHC (both pos. vs all other) 1.77 1.04-3.05 0.034 1.58 0.86-2.91 0.14
D) E-CMF vs E-T-CMF 1.13 0.73-1.75 0.59 1.53 0.89-2.26 0.12
Nodal involvement (≥ 4 vs 0-3) 3.62 1.78-7.34 < 0.001 2.87 1.29-6.40 0.010
Hormone receptor status (pos. vs neg.) 0.51 0.31-0.84 0.009 0.45 0.25-0.81 0.008
Ki67 (high vs low) 2.05 0.99-4.21 0.051 4.35 1.34-14.18 0.015
HER2&TOP2A gene (both ampl. vs all other) 0.13 0.02-0.96 0.046 0.23 0.03-1.74 0.15
HER2&TOP2A mRNA (high vs low) 2.41 1.31-4.42 0.005 2.83 1.42-5.63 0.003
HER2&TopoIIa IHC (both pos. vs all other) 1.36 0.68-2.70 0.38 0.92 0.42-2.18 0.92
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cule is the protein and not its precursor nucleic acids
but a prognostic role for TopoIIa protein could not be
demonstrated so far in large patient series, probably
because of differences in the performance and evalua-
tion of immunohistochemical assessments (reviewed in
[57]). Nevertheless, TOP2A mRNA levels were strongly
associated with TopoIIa protein expression in our series,
which at least indicates effective translation of TOP2A
mRNA in the majority of the cases.
In line with the role of TOP2A in cell proliferation
(reviewed in [12,58]), we observed strong associations of
the proliferation marker Ki67 and tumor grade (which is
characterized by Ki67 labelling) with TopoIIa protein
and TOP2A mRNA levels. High Ki67 scores coinciding
with TopoIIa protein (over)expression have been
reported for breast carcinomas as reflecting tumor pro-
liferation status [50,52,57,59], while the adverse prognos-
tic impact of Ki67 in breast cancer is well established
(reviewed in [60]). With respect to the strong associa-
tion between Ki67 and TOP2A mRNA, which was also
reported in a microarray profiling study [61], it might
be argued that the herein observed adverse prognostic
value of TOP2A mRNA reflects its strong association
with high proliferation rates. This may in part be true,
as previously suggested for TopoIIa protein as well [62].
However, while Ki67 was an unfavorable prognosticator
for both DFS and OS, the adverse prognostic effect of
TOP2A mRNA was limited to OS. In fact, this latter
finding was the only contrasting point between the pre-
sent study involving high-risk early breast cancer in
comparison to low-risk early breast cancer, where
TOP2A mRNA was unfavourably associated with metas-
tasis-free survival [36]. To understand the long term
influence of TOP2A expression on patient outcome, we
need to consider newer functional aspects of TopoIIa
protein and how these affect the fate of cancer cells
when attacked by cytotoxic agents, such as anthracy-
clines (reviewed in [58,63]). It seems that, according to
its molecular environment (among other parameters,
TopoIIb and DNA repair capacity), TopoIIa protein may
contribute to the large array of genomic aberrations
observed in advanced cancers, including alterations of
the TOP2A gene itself, as theya r ef o u n da ti n c r e a s i n g
rates with progressing tumor size ([64] and present
study). At present, several questions regarding TOP2A
in cancer cells remain unanswered, such as, how are
TOP2A amplified genes regulated, whether genes are
amplified in one piece or in fragments, or whether they
lack regulatory regions, what are the genomic profiles of
relapsed/metastatic vs. primary tumors, especially if
treatment has been administered, and so on. Genomic
profiles of higher resolution than obtained with FISH/
CISH probes (which detect additional genes than the
ones they are meant for anyway) would be required for
these studies, while interesting data on genomic patterns
in relevance to breast cancer subtypes have already been
offered [65] and await further evaluation.
In terms of predicting response to paclitaxel, none of
the TOP2A parameters examined was related to patient
outcome. This was somehow expected, since the addi-
tion of this drug to the epirubicin containing treatment
schemes did not offer a significant advantage for dis-
ease-free or overall survival in the same patient cohort
[17], while no association was observed between TOP2A
status and response to taxanes in the neo-adjuvant set-
ting as well [66]. HER2 status (gene amplification and/
or protein overexpression) and HER2 mRNA expression
were not related to benefit from the taxane treatment in
the present study. Relevant HER2 mRNA expression
data could not be retrieved from the literature. The pre-
sent HER2 status data seem to be in contrast to pre-
v i o u sr e p o r t s[ 8 , 6 6 ] ,a sw e l la st ot h ef i n d i n g sf r o mt h e
CALGB 9344/INT0148 adjuvant trial on node-positive
patients who were treated with doxorubicin/cyclopho-
sphamide with or without paclitaxel, probably due to
clinical context, methodological and treatment adminis-
tration differences. In addition, Ki67 was also not asso-
ciated with response to paclitaxel in our series, which
does not support a previously suggested taxane-predic-
tive role of this marker [60].
The adverse prognostic impact of high HER2 mRNA
expression, for the same patient cohort, has already
been published by our group [67]. In comparison to
HER2 mRNA, HER2 status was associated with patient
outcome as a single variable but lost its prognostic sig-
nificance upon multivariate analysis, in line with pre-
vious reports in the same treatment setting [39,68,69]. It
seems that HER2 mRNA remains the most significant
prognostic HER2 parameter, and various assays for the
relative quantification of HER2 mRNA expression by
qRT-PCR, in the single [26,48,70] or multiplex [71,72]
mode have already been developed and evaluated, while
HER2 mRNA is included in the Recurrence Score
obtained by Oncotype DX [73]. In this study, high
HER2 mRNA expression was an independent unfavor-
able prognostic factor, especially in terms of predicting
relapse. Most interestingly, though, when examining
high mRNA expression for both HER2 and TOP2A as a
binary variable in the same tumor, this co-expression
marker was strongly associated with shorter disease-free
and overall survival, while it emerged as a new indepen-
dent adverse prognostic factor in adjuvantly treated
breast cancer patients. Of note, although the HER2 part
of the high HER2/TOP2A mRNA co-expression marker
is related to HER2 gene amplification, the TOP2A part
is evidently not, as described throughout this manu-
script. The biological background underlying this
Fountzilas et al. Journal of Translational Medicine 2012, 10:10
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Page 18 of 21interaction is currently unknown and may be related to
the conditions driving TOP2A (over)expression in the
absence of gene amplification, as described above. It
should also be noted that this combined marker is
based on cohort-dependent cut-offs that were set for
defining high mRNA expression for HER2 and TOP2A;
hence, its validation in independent and larger patient
cohorts is mandatory.
Conclusion
In conclusion, this study confirms the favorable prog-
nostic value of HER2/TOP2A co-amplification and the
adverse prognostic value of high TOP2A mRNA expres-
sion extending it to the adjuvant treatment setting in
early high-risk breast cancer. HER2 and TOP2A amplifi-
cation do not share the same effect on their downstream
molecules, with consistent patterns of HER2 mRNA and
protein expression according to HER2 amplification, but
inconsistent patterns in the case of TOP2A. We are in
the process of validating these findings in a larger phase
I I Is t u d yw i t hm o r et h a n1 , 0 0 0r a n d o m i z e dp a t i e n t s .
The strong adverse prognostic impact of high HER2/
T O P 2 Am R N Ac o - e x p r e s s i o nneeds further validation
in studies designed to evaluate markers predictive of
response to anthracyclines.
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